Aytu Bioscience Inc (NASDAQ:AYTU) Allots Additional 2 Million Shares to The Underwriters

0
514

Aytu Bioscience Inc (NASDAQ:AYTU) has allotted additional 2 million shares to the underwriters as per the terms of $12 million public offering held on March 6, 2018. The total proceeds of the shares sale of the company are estimated at $12.9 million before deducting the commissions, offering expenses and underwriting discounts.

The company has appointed Joseph Gunnar & Co., LLC as the book running manager for the public offering. It has appointed Fordham Financial Management, Inc as lead manager for the public offering.

Aytu Bioscience Inc Explains the Benefits of Natesto therapy for Men

Aytu Bioscience has explained about the positive health benefits of Natesto Therapy for men at ENDO 2018 on March 18, 2018. The Natesto Therapy is used to restore the normal testosterone levels in hypo-gonadal men. But, it will not increase the levels of dihydrotestosterone and testosterone metabolites estradiol.

The presentation is conducted by Dr. Alan D. Rogol, MD, Endocrinology Department, University of Virginia. According to the doctor, the Natesto treatment does not cause any side effects. The E2 and DHT have returned to the normal levels in a 24 hour period.

The CEO of Aytu Bioscience, Mr. Josh Disbrow has said the clinical evidence further supports the Natesto therapy to reinstate normal testosterone levels in hypogonadal men without any side effects. Men receiving the testosterone therapy usually undergoes a change in estradiol and DHT. But, in the case of Natesto therapy administered to men has proven that it is safe.

A brief Information about Aytu Bioscience Inc

The commercial life stages company – Aytu Bioscience Inc is engaged in the commercialization of innovative products in urology on a large scale across the world. The company’s products are mainly aimed at improving sexual wellness, vitality, and health of reproductive organs.

The company sells the FDA approved prescription products in the US. The FDA approved imaging agent – ProstaScint is used for the detection of prostate cancer and staging applications. It also sells FDA approved Natesto formulation to restore testosterone hormones in men.

Aytu Bioscience is also engaged in the development of an innovative semen analysis system MiOXSYS to reduce oxidative stress and promote male fertility.

LEAVE A REPLY

Please enter your comment!
Please enter your name here